The effect of Shenlingbaizhu powder for improvement the CD3+ and CD4+ cell counts and quality of life in gastric cancer patients
-
摘要: [目的]观察参苓白术散对胃癌术后化疗患者生活质量及CD3+和CD4+细胞数量的影响。[方法]将75名胃癌患者随机分为治疗组(n=37)和对照组(n=38),治疗组在西医常规治疗的基础上予参苓白术散中药汤剂口服治疗,对照组采用西医常规治疗:手术+化疗。比较2组治疗前后QOL生活质量评分、CD3+细胞数量和CD4+细胞数量及II级以上毒副反应。[结果]2组治疗后的生活质量评分较治疗前有所升高(P＜0.05),但是治疗组生活质量评分的改善程度较对照组高(P＜0.05)。治疗组治疗前后CD3+和CD4+细胞数量差异有统计学意义(P＜0.05),而对照组治疗前后CD3+和CD4+细胞数量差异无统计学意义(P＞0.05),且治疗组治疗前后的CD3+和CD4+细胞数量的差值与对照组比较差异有统计学意义(P＜0.05)。治疗组和对照组在白细胞下降、血小板、血红蛋白下降等II及以上的毒副反应差异无统计学意义(P＞0.05)。在II级以上胃肠道毒副反应方面差异有统计学意义(P＜0.05)。[结论]参苓白术散能有效的改善胃癌术后化疗患者的生活质量,提高患者CD3+和CD4+细胞数量,并且能降低化疗过程中出现的胃肠道不良反应。Abstract: [Objective]To observe the effect of Shenlingbaizhu powder for improving the CD3+ and CD4+ cell counts and quality of life in gastric cancer patients.[Methods]75 patients with gastric cancer were randomly divided into treatment group(n=37)and control group(n=38).The treatment group received Shenlingbaizhu Powder plus routine treatment,while the control group received routine treatment.The routine treatment inclued surgery and chemotherapy.The quality of life was assessed by the QOL scale before and after treatment.Besides,the CD3+ and CD4+ cell counts were compared between the two groups.And the side effect also was assessed during the treatment.[Results]The score of the QOL betweeen two groups were statisfically sigificant after the treatment(P＜0.05),and the treatment group was higher than the control group(P＜0.05).The difference in pre-/post-treatment of the CD3+ and CD4+ cell number was statistically significant differences between the treatment group and the control group(P＜0.05).And the side effect of gastrointestinal reaction was lower in the treatment group than the control group(P＜0.05).[Conclusion]The effect of Shenlingbaizhu Powder can not only improve the CD3+ and CD4+ cell counts,but also the qulity of life in gastric cancer patients.And it can help prevent the side effect of gastrointestinal reaction.
-
Key words:
- The Shenlingbaizhu Powder /
- gastric cancer /
- the qulity of life /
- CD3+ /
- CD4+
-
-
[1] 中国临床肿瘤学会抗肿瘤药物安全管理专家委员会, 中国抗癌协会胃癌专业委员会, 中国抗癌协会肿瘤病理专业委员会。HER2阳性晚期胃癌分子靶向治疗的中国专家共识 (2016版)[J].临床肿瘤学杂志, 2016, 21 (9):831-839.
[2] Torre L A, Bray F, Siegel R L, et al.Global cancer statistics, 2012[J].CA Cancer J Clin, 2015, 65 (2):87-108.
[3] 中华人民共和国国家卫生和计划生育委员会.胃癌规范化诊疗指南 (试行)[J].中国医学前沿杂志 (电子版), 2013 (8):56-63.
[4] 李晓冰, 崔利宏, 陈玉龙, 等.参苓白术散对溃疡性结肠炎小鼠肠道调节性T细胞免疫调节作用[J].中成药, 2014, 36 (6):1295-1297.
[5] 袁丕瑞.参苓白术散对免疫抑制小鼠免疫功能的影响研究[J].临床合理用药杂志, 2011, 4 (29):67-68.
[6] 陈桂芬.参苓白术散加减改善乳腺癌术后化疗致毒副反应及免疫功能低下的临床研究[J].中国现代医药杂志, 2016, 18 (4):1-4.
[7] Miller A B, Hoogstraten B, Staquet M, et al.Reporting results of cancer treatment[J].Cancer, 1981, 47 (1):207-214.
[8] 陈万青, 郑荣寿, 张思维, 等.2013年中国恶性肿瘤发病和死亡分析[J].中国肿瘤, 2017, 26 (1):1-7.
[9] Okuno K, Tanaka A, Shigeoka H, et al.Suppression of T-cell function in gastric cancer patients after total gastrectomy with splenectomy:implications of splenic autotransplantation[J].Gastric Cancer, 1999, 2 (1):20-25.
[10] 王宏星, 李建平.胃癌术后八珍汤加减辅助肠内营养对生长激素、营养状况及免疫功能的影响[J].中国中西医结合杂志, 2011, 31 (10):1317-1321.
[11] 罗爱华, 张高锋.参苓白术散在局部晚期宫颈癌根治性放疗联合铂类药物化疗中的临床意义[J].中国现代医学杂志, 2016, 26 (17):125-129.
[12] 易良杰, 李升伟, 何冬梅.加味参苓白术散口服联合白细胞介素-2腹腔灌注治疗卵巢癌相关腹水的临床观察[J].广州中医药大学学报, 2017, 34 (1):31-34.
[13] 郝悦.加味参苓白术散对卵巢癌术后化疗减毒作用的临床研究[D].辽宁中医药大学, 2011.
-
计量
- 文章访问数: 183
- PDF下载数: 183
- 施引文献: 0
下载: